Clinical Trial Update: Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 randomized study evaluating oxaliplatin as second-line therapy for pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sanofi | Conditions: Pancreatic Neoplasms | Phase 3 | Status: COMPLETED